Biocon features in the ASIA IP ELITE list for the fourth consecutive year
Biocon Biologics debuts on the ASIA IP ELITE 2019 list
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sandoz
Price caps are a band aid hiding larger issues
Pharma companies should not be the ones held responsible for the high prices of medicines
Novartis’s Sandoz licenses proposed multiple sclerosis biosimilar
The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS)
Sandoz, Macleods Pharma recall two drugs made in India
The US FDA Enforcement Report for the week of February 17 said that the class III voluntary recall is nationwide
US drug firm…
EMA accepts Sandoz application for biosim etanercept
The EMA's acceptance follows recent US FDA regulatory submission acceptance
Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by FDA
Proposed biosimilar pegfilgrastim filing is the second of ten regulatory filings planned over the next three years
Sandoz, a…
Sandoz launches Zarxio, the first biosimilar in US
Sandoz One Source, a patient services centre, was also launched
Zarxio by Sandoz, a Novartis company, is now available in the US.…
Pfizer India to shut down Thane plant from September 16
Sandoz India's Turbhe plant to down shutters by December 2016
CPhI Worldwide announces members of its 2015 expert panel
Kurt Nielson (Catalent), Vivek Sharma (Piramal) and Alan Sheppard (IMS Health) join panel
CCI approves multi-billion dollar deal between GlaxoSmithKline and Novartis
It involves acquisition of GSK's portfolio of oncology products by Novartis for $16 billion